H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12
H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 23.4%
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Maintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical Data
Express News | HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
Jefferies Maintains IGM Biosciences(IGMS.US) With Buy Rating, Maintains Target Price $48
Jefferies analyst Roger Song maintains $IGM Biosciences(IGMS.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 31.7% and a tot
IGM Biosciences IGMS +36% Acquisition Rumors; Biodexa BDRX -45% Warrants Exercise
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersIGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDA
IGM Biosciences up 40% Following Biogen HI-Bio Buy
CureVac, Oragenics, IGM Biosciences Among Healthcare Movers
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Clinical ...
Express News | Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
IGM Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 119.3% Wedbush → $20 Reiterates Outperform → Outperform 04/18/2024 31.58% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)
Express News | IGM Biosciences Inc : RBC Cuts Target Price to $20 From $21
IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
04:42 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
Express News | IGM Biosciences Inc - Expects to End 2024 With Balance of $180 Million in Cash and Investments
Express News | IGM Biosciences - as a Result of Refocusing of Sanofi Collaboration Announced in April, Expects to Recognize FY Collaboration Revenue of $63 Mln